Filtered By:
Condition: Thrombosis
Nutrition: Vitamins
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 899 results found since Jan 2013.
Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients
ConclusionsWe report the largest series of cerebral vein thrombosis patients treated with dabigatran. Clinical outcome was excellent in most patients and not different from other studies. Dabigatran could possibly be considered an alternative to warfarin; nevertheless, further prospective assessment with randomized controlled studies is warranted.
Source: International Journal of Stroke - February 1, 2015 Category: Neurology Authors: Marcelo D. Mendonça, Raquel Barbosa, Vera Cruz‐e‐Silva, Sofia Calado, Miguel Viana‐Baptista Tags: Research Source Type: research
In people with atrial fibrillation receiving antithrombotics, short-term non-steroidal anti-inflammatory drug exposure increases risk of serious bleeding
Commentary on: Lamberts M, Lip GYH, Hansen ML, et al. Relation of non-steroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy Ann Intern Med 2014;161:690–8. Implications for practice and research Short courses of non-steroidal anti-inflammatory drugs (NSAIDs) should be used with caution in patients with atrial fibrillation (AF) already taking antithrombotic therapy for stroke prevention since there is an increased risk of serious bleeding and clot formation. Research needs to be carried out on whether combined NSAID and non-v...
Source: Evidence-Based Nursing - December 15, 2015 Category: Nursing Authors: Myat, A. Tags: GI bleeding, Adult nursing, Drugs: cardiovascular system, Pain (neurology), Stroke, Ischaemic heart disease, Pain (palliative care), Pain (anaesthesia), Drugs: musculoskeletal and joint diseases, Arrhythmias Source Type: research
New reversal agent for factor Xa inhibitors shows promise
Commentary on: Siegal DM, Curnette JT, Connolly SJ, et al.. Andexanet alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med 2015;373:2413–24. Context Direct oral anticoagulants (DOACs) have emerged as alternatives to vitamin K-antagonists (eg, warfarin) for the long-term management of stroke prevention for non-valvular atrial fibrillation or venous thromboembolic disease. Favourable side-effect profiles and absence of therapeutic monitoring are important benefits of these newer agents. Warfarin is readily reversed with fresh frozen plasma (FFP) or prothrombin complex concentrates.1 The first reversal ag...
Source: Evidence-Based Medicine - May 22, 2016 Category: Internal Medicine Authors: Ghadimi, K., Welsby, I. J. Tags: Clinical trials (epidemiology), Immunology (including allergy), Drugs: cardiovascular system, Stroke, Venous thromboembolism, Unwanted effects / adverse reactions Therapeutics/Prevention Source Type: research
Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation.
PMID: 27307147 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 15, 2016 Category: Hematology Authors: Wilson MR, Parakramawansha R, Quinn TJ, Tait RC Tags: Thromb Haemost Source Type: research
The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non‐valvular atrial fibrillation: comment
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 30, 2016 Category: Hematology Authors: Simon Mantha, Stephan Moll, Patrick Hilden, Sean Devlin, Adam Rose Tags: Letter ‐ to the Editor Source Type: research
Safety of OnabotulinumtoxinA Treatment With Concomitant Antithrombotic Therapy in Patients With Post-stroke Spasticity: A Pooled Analysis of Randomized, Double-Blind Studies (S56.008)
Conclusions:There is no apparent increased risk of bleeding complications in patients on antithrombotics following IM onabotA treatment; nonetheless, careful observation of the injection site and patient education of the potential for bleeding complications remain warranted.Study Supported by: Allergan plc, Dublin, IrelandDisclosure: Dr. Dimitrova has received personal compensation for activities with Allergan as an employee. Dr. Dimitrova holds stock and/or stock options in Allergan. Dr. James has received personal compensation for activities with Allergan and Chase Pharmaceuticals as an employee. Dr. Liu has received per...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Dimitrova, R., James, L., Liu, C., Orejudos, A., Yushmanova, I., Brin, M. Tags: Movement Disorders: Huntington ' s Disease and Drug-Induced Dyskinesias Source Type: research
Contemporary Management of Stroke Prevention in Atrial Fibrillation Following the European Society of Cardiology Guidelines
Prevention of ischaemic stroke has long been central to the management of patients with atrial fibrillation (AF), historically relying on the use of vitamin K antagonists (VKAs) or antiplatelet agents depending on the risk of thromboembolism. Difficulties associated with maintaining VKAs in therapeutic range and the perceived risk of bleeding have been highlighted as reasons to withhold oral anticoagulation (OAC) and these issues have partly been addressed by the introduction of non-vitamin K antagonist oral anticoagulants (NOACs).
Source: Radcliffe Cardiology - August 14, 2017 Category: Cardiology Authors: mehul Source Type: research
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
The safety of intravenous thrombolysis in patients taking rivaroxaban has not been well established. We retrospectively analyzed the outcomes of all patients who received thrombolytic therapy in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). A review of medical and adverse event records for patients receiving thrombolytic therapy while enrolled in ROCKET AF was performed to determine their baseline characteristics, indications for thrombolysis, and type of agent used.
Source: The American Journal of Cardiology - August 7, 2017 Category: Cardiology Authors: Sean T. Chen, Anne S. Hellkamp, Richard C. Becker, Scott D. Berkowitz, G ünter Breithardt, Keith A.A. Fox, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan P. Piccini, Daniel E. Singer, Manesh R. Source Type: research
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants Expert opinion of the Societe Francaise de Neurologie Vasculaire (SFNV) French Vascular Neurology Society and the Groupe Francais d'etudes sur l'Hemostase et la Thrombose (GFHT) French study Group on Haemostasis and Thrombosis
ConclusionsIn this expert opinion paper, we suggest that IVT can be performed in patients selected according to the time elapsed since the drug was last taken, renal function, type of hospital where the patient is admitted and plasma concentration of DOAC.This article is protected by copyright. All rights reserved.
Source: European Journal of Neurology - January 23, 2018 Category: Neurology Authors: Emmanuel Touz é, Yves Gruel, Isabelle Gouin‐Thibault, Emmanuel De Maistre, Sophie Susen, Pierre Sie, Laurent Derex Tags: Original Article Source Type: research
Rivaroxaban in the cardiovascular world: a direct anticoagulant useful to prevent stroke, and venous and arterial thromboembolism.
Authors: Seoane L, Cortés M, Aris Cancela ME, Furmento J, Baranchuk A, Conde D
Abstract
INTRODUCTION: Until recently, vitamin K antagonists were the only drugs available for long-term anticoagulation. The use of these drugs is laborious due to their variable pharmacokinetics and pharmacodynamics. The advent of direct oral anticoagulants has produced a paradigm shift due to their low incidence of drug interactions, their stable plasma levels and their lack of monitoring. Rivaroxaban, a factor Xa inhibitor, has been tested in different clinical scenarios and has proved to be effective and safe, even increasing the s...
Source: Expert Review of Cardiovascular Therapy - June 6, 2018 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research
Malignant Left Atrial Appendage Morphology: Current Classification vs H-L System
In non-valvular atrial fibrillation (AF), more than 90% of thrombus formation occurs in the left atrial appendage (LAA).1-3 Current guidelines have established direct oral anticoagulants (DOACs) as the treatment of choice in patients with AF and high risk of stroke or transient ischemic attack (TIA), while vitamin K antagonists (VKA) can be considered in patients not suitable for DOACs.4,5 This strategy significantly reduces the risk of thromboembolism; however, there is a subset of patients that suffer recurrent embolic strokes despite appropriate anticoagulant therapy, known as malignant LAA.
Source: Journal of Stroke and Cerebrovascular Diseases - December 30, 2020 Category: Neurology Authors: Paloma Parra-D íaz, Luisa Salido-Tahoces, Ana Pardo-Sanz, Álvaro Beltrán-Corbellini, Fernando Rodríguez-Jorge, Juan Luis Chico-García, Sebastián García-Madrona, Consuelo Matute-Lozano, Rocío Vera-Lechuga, Antonio Cruz-Culebras, Jaime Masjuan, Alic Source Type: research
Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study
Appropriate and timely anticoagulant therapy with vitamin K antagonists (VKAs) or non-vitamin K oral antagonists (NOACs) is essential for stroke prevention in non-valvular atrial fibrillation (NVAF). Comparati...
Source: Thrombosis Journal - July 4, 2022 Category: Hematology Authors: Christopher Hohmann, Magnus Lutz, Sheila Vignali, Kathrin Borchert, Karolin Seidel, Sebastian Braun, Stephan Baldus and Michael N äbauer Tags: Research Source Type: research
Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration.
H, Kirchhof P, Korompoki E, Krieger DW, Lip GYH, Løchen ML, Mairesse GH, Montaner J, Neubeck L, Ntaios G, Piccini JP, Potpara TS, Quinn TJ, Reiffel JA, Ribeiro ALP, Rienstra M, Rosenqvist M, Sakis T, Sinner MF, Svendsen JH, Van Gelder IC, Wachter R, Wijeratne T, Yan B
Abstract
Cardiac thromboembolism attributed to atrial fibrillation (AF) is responsible for up to one-third of ischemic strokes. Stroke may be the first manifestation of previously undetected AF. Given the efficacy of oral anticoagulants in preventing AF-related ischemic strokes, strategies of searching for AF after a stroke using ECG monitoring fol...
Source: Circulation - November 25, 2019 Category: Cardiology Authors: Schnabel RB, Haeusler KG, Healey JS, Freedman B, Boriani G, Brachmann J, Brandes A, Bustamante A, Casadei B, Crijns HJGM, Doehner W, Engström G, Fauchier L, Friberg L, Gladstone DJ, Glotzer TV, Goto S, Hankey GJ, Harbison JA, Hobbs FDR, Johnson LSB, Kame Tags: Circulation Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Percutaneous Left Atrial Appendage Suture Ligation Not Ready for Prime Time ∗
Novel approaches to reduce stroke risk with oral anticoagulant medications or interventions are of the utmost importance to improve the quality of care for patients with atrial fibrillation (AF). Oral anticoagulation with vitamin K antagonists and, more recently, with novel oral anticoagulants (NOACs) has led to a remarkable reduction of stroke risk; however, some of the benefits with NOACs are counterbalanced by increased bleeding risks. The idea of developing interventions that reduce stroke risk but avoid long-term oral anticoagulation and thereby avoid increasing the bleeding risk appears very reasonable and attractive...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - August 4, 2014 Category: Cardiology Source Type: research
